Who might be right for Oxbryta?

Oxbryta® Patient Profile - not an actual patient

Not an actual patient

Find appropriate sickle cell disease (SCD) patients based on your practice

Please select the most common characteristics of the patients with SCD you treat to learn more

Currently taking hydroxyurea (HU) therapy

Age group

Lucy is a patient who has similar characteristics to the HOPE trial population.

Oxbryta® Patient Profile: Lucy - not an actual patient

Not an actual patient

Lucy

  • 30-year-old Hispanic with SCD genotype HbSS

Relevant past medical history:

  • Received 2 blood transfusions in the past year
  • History of 3 vaso-occlusive crises (VOCs) in the past year, 1 of which required a hospital admission

Treatment of SCD:

  • Treated with HU, on maximum tolerated dose

Baseline lab workup:

  • Hb = 8.0 g/dL
  • Indirect bilirubin = 9.5 mg/dL
  • Reticulocytes = 12%

Brianna could be a potential patient because she has been treated with the max dose of HU and Oxbryta is indicated for patients as young as 12.

Oxbryta® Patient Profile: Brianna - not an actual patient

Not an actual patient

Brianna

  • 12-year-old African American with SCD genotype HbSS
  • She likes to play soccer

Relevant past medical history:

  • Presented with 1 vaso-occlusive crisis (VOC) in the past year

Treatment of SCD:

  • Treated with HU, on maximum tolerated dose
  • Folic acid

Baseline lab workup:

  • Hb = 7.5 g/dL
  • Indirect bilirubin = 4.0 mg/dL
  • Reticulocytes = 9.0%

William has a busy schedule and has had >2 vaso-occlusive crises (VOCs) in the past year, like 58% of patients in the HOPE trial.

Oxbryta® Patient Profile: William - not an actual patient

Not an actual patient

William

  • 40-year-old African American with SCD genotype HbSβ0 thalassemia
  • He works as a consultant, traveling each week

Relevant past medical history:

  • Cannot receive blood transfusions due to alloantibodies
  • History of 3 VOCs in the past year and 2 episodes of acute chest syndrome

Treatment of SCD:

  • Discontinued HU therapy 5 years ago due to work lifestyle and inability to adhere to frequent lab monitoring

Baseline lab workup:

  • Hb = 7.0 g/dL
  • Indirect bilirubin = 6.5 mg/dL
  • Reticulocytes = 9.0%

Tyler will be transitioning to a new HCP and moving away from his parents. The safety profile observed in pediatric patients 12 to <17 years of age treated with Oxbryta was similar to that seen in adult patients.

Oxbryta® Patient Profile: Tyler - not an actual patient

Not an actual patient

Tyler

  • 18-year-old African American with SCD genotype HbSC
  • Going away to college in 6 months
  • Parents are concerned about transitioning to another HCP away from home

Relevant past medical history:

  • History of 2 vaso-occlusive crises (VOCs) in the past year

Treatment of SCD:

  • Patient has declined HU treatment in the past

Baseline lab workup:

  • Hb = 10.0 g/dL
  • Reticulocytes = 4.0%

Get the latest information about Oxbryta delivered to your inbox